The effects of oral arginine on its metabolic pathways in Sprague Dawley rats.
Oral arginine supplements are popular mainly for their presumed vasodilatory benefit. Arginine is a substrate for at least four enzymes including nitric oxide synthase and arginase, but the impact of oral supplements on its different metabolic pathways is not clear. Deficiencies of arginine metabolizing enzymes are associated with conditions such as hyperammonemia, endothelial dysfunction, CNS and muscle dysfunction, which complicates the use of oral arginine supplements. We examined the effect of L-arginine and D-arginine, each at 500 mg/kg/day in drinking water administered for 4 weeks to separate groups of 9 week old male Sprague-Dawley rats. We quantified the expression of enzymes and plasma, urine and organ levels of various metabolites of arginine. L-arginine significantly decreased cationic transporter-1 expression in the liver and the ileum, and increased endothelial nitric oxide synthase expression in the aorta and the kidney and plasma nitrite levels, but did not affect the mean arterial pressure. L-arginine also decreased expression of arginase II in the ileum, arginine:glycine amidinotransferase in the liver and the kidney, and glyoxalase I in the liver, ileum and the brain, but increased the expression of arginine decarboxylase and polyamines levels in the liver. D-arginine, the supposedly inert isomer, also unexpectedly affected the expression of some enzymes and metabolites. In conclusion, both L- and D-arginine significantly affected enzymes and metabolites in several pathways that use arginine as a substrate and further studies with different doses and treatment duration are planned to establish their safety or adverse effects to guide their use as oral supplements.